B-Cell Lymphomas Coverage from Every Angle

Published Medical Literature

R-CHOP as Front-Line Therapy for Primary Mediastinal LBCL: A View From Jordan
Identifying Factors to Predict Prognosis in Patients With Follicular Lymphoma
Study Explores the Predictive Use of Tumor-Associated Macrophages in DLBCL
Rare MALT Lymphoma in the Thymus and Lung: Case Report
The Cost of CAR T-Cell Therapy in the Second-Line or Third-Line Setting in DLBCL
Bispecific Antibody Glofitamab Under Study in Relapsed or Refractory DLBCL
Clinical Laboratory Mutation Analysis as Predictive Measure in Aggressive B-Cell Lymphomas
Can Real-World Data Be Used to Determine the Effectiveness of Treatments in DLBCL?
Atezolizumab-Based Regimen Under Study in Follicular Lymphoma
Could Zanubrutinib Be an Alternative to Patients With BTK Inhibitor–Intolerant B-Cell Malignancies?
What Can Be Learned About Primary Gastrointestinal DLBCL From Whole-Exome Sequencing?
Using Epigenetic Markers as Prognostic Predictors in Patients With DLBCL
Weighing the Cost-Effectiveness of Immunotherapy Combinations for Patients With DLBCL
Front-Line Therapies With Liposomal Doxorubicin for Advanced B-Cell Lymphomas
What Do We Know About Leukemic Involvement in High-Grade B-Cell Lymphoma?
Can the Malignancy of B-Cell Lymphoid Aggregates Be Determined Via IGH/IGK Analysis?
Exploring Potential Combination Therapies to Overcome Venetoclax Resistance in Mantle Cell Lymphoma
A Novel Minimally Invasive Risk Assessment Tool for Patients With Large B-Cell Lymphoma
Does BTK Inhibitor Therapy Increase the Risk of HBV Reactivation in Those With Advanced DLBCL?
Conditioning Chemotherapy, Lymphocyte Count Kinetics, and Outcomes in LBCL
High-Risk Extranodal Marginal Zone Lymphoma: Novel Predictive Model Under Study
Polypharmacy and Potentially Inappropriate Medications: Predictors of Frailty in Older Patients With Hematologic Malignancies?
ASTCT Panel Opinion: Use of CD19 CAR T Cells in Large B-Cell Lymphoma
Real-World Study in Mantle Cell Lymphoma: Treatment Patterns and Outcomes
Overcoming Resistance to TP53-Mediated Chemoimmunotherapy in B-Cell Malignancies
Risk of Breakthrough COVID Infection After Vaccination in Patients With Hematologic Malignancies
First-Line Treatment Patterns and Outcomes Offer Considerations for Future Trial Design in Mantle Cell Lymphoma
Are Bone Marrow Biopsies Relevant for Response Assessment in Patients With Follicular Lymphoma?
Use of Tisagenlecleucel at Outpatient Facilities for Patients With Lymphoma
First-Line Radioimmunotherapy for Follicular Lymphoma: Long-Term Follow-up
Triggering Anticancer Immunity in DLBCL With Combination Inhibition of CD47/SIRPα
Does a Tamoxifen-Sensitive Target Exist in Diffuse Large B-Cell Lymphoma?
Is Frailty a Predictor of Survival in Patients With Newly Diagnosed DLBCL?
Chemotherapy-Free GALEN Combination for Advanced Follicular Lymphoma
Dual-Targeted Chimeric Antigen Receptor NK-92 Cells Under Study in B-Cell Malignancies
Identifying the Optimal Doses of Ibrutinib and Venetoclax in Resistant Mantle Cell Lymphoma
Predicting Survival Outcomes With PET Radiomics in Diffuse Large B-Cell Lymphoma
From the Haematological Malignancy Research Network: Expanded Database May Yield Insights in B-Cell Lymphomas
Clinical Characteristics of Diffuse Large B-Cell Lymphoma Manifesting in the Jaw
Does Microenvironment Impact the Pathogenesis of MALT Lymphomas?
Does the MYC/MYB/ZDHHC11 Network Impact the Growth of B-Cell Malignancies?
First-Line Ibrutinib Plus Rituximab in Elderly Patients With Mantle Cell Lymphoma
Loncastuximab Tesirine-lpyl for DLBCL: Quality of Life for Older Versus Younger Patients
Prognostic Analyses of Genetic Subtypes Within Diffuse Large B-Cell Lymphoma
Immunogenicity Profile of Tisagenlecleucel in Diffuse Large B-Cell Lymphoma
Biomarkers and Pathways Associated With B-Cell Lymphoma
Exploring the Function of Transcription Factor 3 and Histone Deacetylase 3 in Burkitt Lymphoma
Impact of FLI1 Expression Levels in Germinal Center–Derived DLBCL
Heterologous SARS–CoV-2 Vaccination for Patients With B-Cell Lymphoma
Zanubrutinib Monotherapy for Mantle Cell Lymphoma: Pooled Analysis of Two Trials
Phase II Trial of Combination Therapy for Children and Adolescents With Primary Mediastinal B-Cell Lymphoma
Polatuzumab Vedotin-piiq–Based Salvage Chemotherapy for DLBCL
The Role of Protein Kinase CK1α in Mantle Cell Lymphoma
Zanubrutinib Versus Standard BTK Inhibitors in B-Cell Malignancy: Pooled Safety Analysis
Early-Phase Study of Combination BTK and PI3K Inhibition as B-Cell Lymphoma Therapy
Polatuzumab Vedotin-piiq–Based Therapy for Previously Untreated DLBCL: POLARIX Trial
Older Patients With Mantle Cell Lymphoma: Phase II Trial Focuses on Ibrutinib Plus Rituximab
Tisagenlecleucel Versus Standard of Care in Second-Line Therapy for Aggressive B-Cell Lymphomas
Evaluation of B-Cell Gene Signatures Using Immunomagnetic Cell Separation
Predictability of MCL1 and BCL2 Expression as Sensitivity Biomarkers in B-Cell Lymphomas
Axicabtagene Ciloleucel Versus Standard-of-Care Therapy for Resistant B-Cell Lymphoma
Prognostic Factors of Rheumatic Disease–Associated DLBCL

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.